{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:51:48Z","timestamp":1791150708152,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI Grant","award":["25K19123"],"award-info":[{"award-number":["25K19123"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Although stereotactic body radiotherapy (SBRT) boost represents a promising treatment option for patients with locally advanced cervical cancer who were considered unsuitable for brachytherapy, its long-term efficacy and safety remain unclear. This study assessed long-term oncologic outcomes and late toxicities in a patient cohort from a previous phase I\/II trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This secondary analysis included 21 patients enrolled in an open-label, multicenter, single-arm, prospective phase I\/II trial between January 2016 and October 2020. Patients with cervical cancer considered unsuitable for intracavitary brachytherapy received whole-pelvic radiotherapy (45\u00a0Gy in 25 fractions), followed by an SBRT boost to the primary tumor (21\u00a0Gy delivered in three consecutive daily fractions). The endpoints of this analysis included long-term oncological outcomes and late radiotherapy-related toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort comprised 21 patients, of whom 52% were aged\u2009\u2265\u200975 years, 81% had clinical stage III disease, and 43% had a maximum primary tumor size\u2009\u2265\u200970\u00a0mm. The median follow-up was 61.1 months (range, 10.4\u2013111.0) for all patients and 71.9 months (range, 60.0\u2013111.0) for surviving patients. The 5-year loco-regional control, progression-free survival, and overall survival rates were 84%, 62%, and 62%, respectively. Grade 3 late toxicity occurred in one patient (urinary tract obstruction), and no grade 4\u20135 toxicities were observed. Six patients experienced grade 2 late toxicities (proctitis, n\u2009=\u20093; fractures, n\u2009=\u20093).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This secondary analysis demonstrated encouraging long-term oncologic outcomes and an acceptable long-term safety profile following SBRT boost. These findings suggest that SBRT may represent a feasible treatment approach in carefully selected patients with locally advanced cervical cancer who are unable or unwilling to undergo brachytherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-026-02089-0","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:13:18Z","timestamp":1791000798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term results of stereotactic body radiotherapy boost in patients with cervical cancer considered unsuitable for intracavitary brachytherapy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5792-3795","authenticated-orcid":false,"given":"Kei","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Furusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Kino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Yasugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko Nemoto","family":"Murofushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"2089_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.brachy.2011.07.003","volume":"11","author":"AN Viswanathan","year":"2012","unstructured":"Viswanathan AN, Thomadsen B, American Brachytherapy Society Cervical Cancer Recommendations Committee, American Brachytherapy Society. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy. 2012;11:33\u201346.","journal-title":"Brachytherapy"},{"key":"2089_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijrobp.2013.05.033","volume":"87","author":"K Han","year":"2013","unstructured":"Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013;87:111\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2089_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5114\/jcb.2021.103583","volume":"13","author":"M Kissel","year":"2021","unstructured":"Kissel M, Fournier-Bidoz N, Henry O, et al. Venezia applicator with oblique needles improves clinical target volume coverage in distal parametrial tumor residue compared to parallel needles only. J Contemp Brachytherapy. 2021;13:24\u201331.","journal-title":"J Contemp Brachytherapy"},{"key":"2089_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5114\/jcb.2021.103584","volume":"13","author":"KN Murofushi","year":"2021","unstructured":"Murofushi KN, Ishida T, Baba K, et al. Impact of pre-brachytherapy magnetic resonance imaging on dose-volume histogram of locally advanced cervical cancer patients treated with radiotherapy including high-dose-rate brachytherapy. J Contemp Brachytherapy. 2021;13:32\u20138.","journal-title":"J Contemp Brachytherapy"},{"key":"2089_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/jjco\/hyy187","volume":"49","author":"K Ito","year":"2019","unstructured":"Ito K, Shimizuguchi T, Karasawa K. Clinical outcomes following conventional external beam radiotherapy boost in Japanese patients with cervical cancer who are ineligible for intracavitary brachytherapy. Jpn J Clin Oncol. 2019;49:270\u20135.","journal-title":"Jpn J Clin Oncol"},{"key":"2089_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s44178-025-00200-5","volume":"4","author":"X Zhang","year":"2025","unstructured":"Zhang X, Lou H. Review of radiotherapy for cervical cancer. Holist Integr Oncol. 2025;4:64.","journal-title":"Holist Integr Oncol"},{"key":"2089_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clon.2017.01.009","volume":"29","author":"LC Mendez","year":"2017","unstructured":"Mendez LC, Leung E, Cheung P, Barbera L. The role of stereotactic ablative body radiotherapy in gynaecological cancers: a systematic review. Clin Oncol (R Coll Radiol). 2017;29:378\u201384.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2089_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ijrobp.2019.10.042","volume":"106","author":"K Albuquerque","year":"2020","unstructured":"Albuquerque K, Tumati V, Lea J, et al. A phase II trial of stereotactic ablative radiation therapy as a boost for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2020;106:464\u201371.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2089_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104789","volume":"213","author":"JL da Silva","year":"2025","unstructured":"da Silva JL, de Miranda AVSS, Arruda GV, et al. Stereotactic body radiotherapy as an alternative to brachytherapy in cervical cancer (SCORE): a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2025;213:104789.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2089_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/cncr.20734","volume":"103","author":"T Nakano","year":"2005","unstructured":"Nakano T, Kato S, Ohno T, et al. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer. 2005;103:92\u2013101.","journal-title":"Cancer"},{"key":"2089_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s11604-024-01566-8","volume":"42","author":"K Ito","year":"2024","unstructured":"Ito K, Nakajima Y, Ogawa H, et al. Phase I\/II study of stereotactic body radiotherapy boost in patients with cervical cancer ineligible for intracavitary brachytherapy. Jpn J Radiol. 2024;42:909\u201317.","journal-title":"Jpn J Radiol"},{"key":"2089_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/jjco\/hyr096","volume":"41","author":"T Toita","year":"2011","unstructured":"Toita T, Ohno T, Kaneyasu Y, et al. A consensus-based guideline defining clinical target volume for primary disease in external beam radiotherapy for intact uterine cervical cancer. Jpn J Clin Oncol. 2011;41:1119\u201326.","journal-title":"Jpn J Clin Oncol"},{"key":"2089_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/jjco\/hyp191","volume":"40","author":"T Toita","year":"2010","unstructured":"Toita T, Ohno T, Kaneyasu Y, et al. A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol. 2010;40:456\u201363.","journal-title":"Jpn J Clin Oncol"},{"key":"2089_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ygyno.2012.04.036","volume":"126","author":"T Toita","year":"2012","unstructured":"Toita T, Kitagawa R, Hamano T, et al. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol Oncol. 2012;126:211\u20136.","journal-title":"Gynecol Oncol"},{"key":"2089_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.radonc.2004.12.015","volume":"74","author":"C Haie-Meder","year":"2005","unstructured":"Haie-Meder C, P\u00f6tter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74:235\u201345.","journal-title":"Radiother Oncol"},{"key":"2089_CR16","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. [Accessed January 5, 2026]."},{"key":"2089_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.clon.2005.10.004","volume":"18","author":"EP Saibishkumar","year":"2006","unstructured":"Saibishkumar EP, Patel FD, Sharma SC, Karunanidhi G, Sankar AS, Mallick I. Results of external-beam radiotherapy alone in invasive cancer of the uterine cervix: a retrospective analysis. Clin Oncol (R Coll Radiol). 2006;18:46\u201351.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2089_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/IGC.0000000000001200","volume":"28","author":"B O'Donnell","year":"2018","unstructured":"O\u2019Donnell B, Shiao JC, Pezzi TA, et al. Stereotactic body radiation therapy, intensity-modulated radiation therapy, and brachytherapy boost modalities in invasive cervical cancer: A study of the national cancer data base. Int J Gynecol Cancer. 2018;28:563\u201374.","journal-title":"Int J Gynecol Cancer"},{"key":"2089_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.rpor.2018.08.005","volume":"23","author":"L Yanez","year":"2018","unstructured":"Yanez L, Ciudad AM, Mehta MP, Marsiglia H. What is the evidence for the clinical value of SBRT in cancer of the cervix? Rep Pract Oncol Radiother. 2018;23:574\u20139.","journal-title":"Rep Pract Oncol Radiother"},{"key":"2089_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-1469-8","volume":"15","author":"E Leung","year":"2020","unstructured":"Leung E, Gladwish A, Sahgal A, et al. Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy. Radiat Oncol. 2020;15:24.","journal-title":"Radiat Oncol"},{"key":"2089_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ygyno.2021.04.010","volume":"161","author":"RJ Hutten","year":"2021","unstructured":"Hutten RJ, Huang YJ, Gaffney DK. Stereotactic body radiotherapy for the treatment of gynecologic malignancies: passing fancy or here to stay? Gynecol Oncol. 2021;161:642\u20134.","journal-title":"Gynecol Oncol"},{"key":"2089_CR22","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/ijgc-2020-002310","volume":"31","author":"M Campitelli","year":"2021","unstructured":"Campitelli M, Lazzari R, Piccolo F, et al. Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review. Int J Gynecol Cancer. 2021;31:1278\u201386.","journal-title":"Int J Gynecol Cancer"},{"key":"2089_CR23","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1136\/ijgc-2019-001104","volume":"30","author":"S Dalwadi","year":"2020","unstructured":"Dalwadi S, Echeverria A, Jhaveri P, et al. Non-invasive stereotactic ablative boost in patients with locally advanced cervical cancer. Int J Gynecol Cancer. 2020;30:1684\u20138.","journal-title":"Int J Gynecol Cancer"},{"key":"2089_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/ijgc-2019-000735","volume":"30","author":"R Lazzari","year":"2020","unstructured":"Lazzari R, Riva G, Augugliaro M, et al. Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy. Int J Gynecol Cancer. 2020;30:607\u201312.","journal-title":"Int J Gynecol Cancer"},{"key":"2089_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s00066-020-01685-x","volume":"197","author":"J Morgenthaler","year":"2021","unstructured":"Morgenthaler J, K\u00f6hler C, Budach V, et al. Long-term results of robotic radiosurgery for non brachytherapy patients with cervical cancer. Strahlenther Onkol. 2021;197:474\u201386.","journal-title":"Strahlenther Onkol"},{"key":"2089_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01877-4","volume":"16","author":"TH Lee","year":"2021","unstructured":"Lee TH, Song C, Kim IA, et al. Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible. Radiat Oncol. 2021;16:148.","journal-title":"Radiat Oncol"},{"key":"2089_CR27","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1080\/01443615.2022.2081790","volume":"42","author":"M Gultekin","year":"2022","unstructured":"Gultekin M, Yilmaz MT, Yuce Sari S, Yildiz D, Ozyigit G, Yildiz F. Stereotactic body radiotherapy boost in patients with cervical cancer. J Obstet Gynaecol. 2022;42:3033\u201340.","journal-title":"J Obstet Gynaecol"},{"key":"2089_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13017-8","volume":"24","author":"M Turna","year":"2024","unstructured":"Turna M, Rzazade R, K\u00fc\u00e7\u00fckmorko\u00e7 E, K\u00fc\u00e7\u00fck N, Cano\u011flu MD, \u00c7a\u011flar HB. Dose escalation with stereotactic body radiotherapy for cervical cancer treatment. BMC Cancer. 2024;24:1281.","journal-title":"BMC Cancer"},{"key":"2089_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.prro.2020.04.002","volume":"10","author":"J Chino","year":"2020","unstructured":"Chino J, Annunziata CM, Beriwal S, et al. Radiation therapy for cervical cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2020;10:220\u201334.","journal-title":"Pract Radiat Oncol"},{"key":"2089_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijrobp.2023.11.007","volume":"119","author":"K Han","year":"2024","unstructured":"Han K, Colson-Fearon D, Liu ZA, Viswanathan AN. Updated trends in the utilization of brachytherapy in cervical cancer in the United States: a surveillance, epidemiology, and end-results study. Int J Radiat Oncol Biol Phys. 2024;119:143\u201353.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02089-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-02089-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02089-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:01:51Z","timestamp":1791147711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-02089-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":30,"alternative-id":["2089"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-02089-0","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KI received payments or honoraria for lectures, presentations, or educational events from Varian Medical Systems. The other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by our institutional ethical review board (approval number 2311 in the research representative institution), and written informed consent was obtained from all patients. This study was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN000036845).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}